Back

SETD2 is an actin lysine methyltransferase

Seervai, R. N. H.; Jangid, R. K.; Karki, M.; Tripathi, D. N.; Jung, S. Y.; Kearns, S. E.; Verhey, K. J.; Cianfrocco, M. A.; Millis, B. A.; Tyska, M. J.; Mason, F. M.; Rathmell, W. K.; Park, I. Y.; Dere, R.; Walker, C. L.

2020-04-14 cell biology
10.1101/2020.04.13.034629 bioRxiv
Show abstract

SET-domain-containing-2 (SETD2) was identified as the methyltransferase responsible for the histone 3 lysine 36 trimethyl (H3K36me3) mark of the histone code. Most recently, SETD2 has been shown to be a dual-function remodeler that regulates genome stability via methylation of dynamic microtubules during mitosis and cytokinesis. Here we show that actin is a bona fide target for methylation by SETD2 in vitro and in cells. Antibodies against the SETD2 trimethyl lysine epitope recognize methylated actin, with this methyl mark localizing to areas of active actin cytoskeleton reorganization in migrating cells. Disruption of this methylation activity causes defects in actin polymerization and impairs collective cell migration. Together, these data identify SETD2 as a multifunctional cytoskeletal remodeler regulating methylation and polymerization of actin filaments, and provide new avenues for understanding how defects in SETD2 drive disease via aberrant cytoskeletal methylation.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.